Blurred Lines: Dysbiosis and Probiotics in the ICU

Chest

Volumn 151, Issue 2, 2017, Pages 492-499

  Morrow, Lee E ^a   Wischmeyer, Paul ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC ASSOCIATED DIARRHEA; BACILLUS; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG SAFETY; DYSBIOSIS; HEPATIC ENCEPHALOPATHY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LACTOBACILLUS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; NECROTIZING ENTEROCOLITIS; NONHUMAN; PANCREATITIS; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SACCHAROMYCES; SEPSIS; SYSTEMATIC REVIEW (TOPIC); URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; CHEMICALLY INDUCED; DIARRHEA; ENTEROCOLITIS, NECROTIZING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; PNEUMONIA, VENTILATOR-ASSOCIATED; SURGICAL WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM; DIARRHEA; DYSBIOSIS; ENTEROCOLITIS, NECROTIZING; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HEPATIC ENCEPHALOPATHY; HUMANS; INTENSIVE CARE UNITS; LACTOBACILLUS; MULTIPLE ORGAN FAILURE; PANCREATITIS; PNEUMONIA, VENTILATOR-ASSOCIATED; PROBIOTICS; SEPSIS; SURGICAL WOUND INFECTION;

EID: 85011564459     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.10.006     Document Type: Review

References (42)

1. 1 Sender, R., Fuchs, S., Milo, R., Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164:3 (2016), 337–340.
2. 2 Klingensmith, N.H., Coopersmith, C.M., The gut as the motor of multiple organ dysfunction in critical illness. Crit Care Clin 32:2 (2016), 203–212.
3. 3 Wischmeyer, P.E., McDonald, D., Knight, R., Role of the microbiome, probiotics, and ‘dysbiosis therapy’ in critical illness. Curr Opin Crit Care 22:4 (2016), 347–353.
4. 4 Dickson, R.P., Singer, B.H., Newstead, M.W., et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nature Microbiol, 1, 2016, e16113.
5. 5 Magill, S.S., Edwards, J.R., Beldavs, Z.G., et al. Prevalence of antimicrobial use in US acute care hospitals, May-September 2011. JAMA 312:14 (2014), 1438–1446.
6. 6 Vincent, J.L., Rello, L., Marshall, J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:21 (2009), 2323–2329.
7. 7 Shimizu, K., Ogura, H., Hamasaki, T., et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci 56:4 (2011), 1171–1177.
8. 8 Gordon, S., Elie Metchnikoff, the man and the myth. J Innate Immun 8:3 (2016), 223–227.
9. 9 Khailova, L., Petrie, B., Baird, C.H., et al. Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. PLoS One, 9, 2014, e97861.
10. 10 Petrof, E.O., Dhaliwal, R., Mananares, W., et al. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med 40:12 (2012), 3290–3302.
11. 11 Manzanares W, Lemieux M, Langois PL, Wischmeyer PE. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis [published online ahead of print August 19, 2016]. Crit Care. http://dx.doi.org/10.1186/s13054-016-1434-y.
12. 12 Siempos, I.I., Ntaidou, T.K., Falagas, M.E., Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 38:3 (2010), 954–962.
13. 13 Barraud, D., Bollaert, P.E., Gibot, S., Impact of the administration of probiotics on mortality in critically ill adult patients; a meta-analysis of randomized controlled trials. Chest 143:3 (2013), 646–655.
14. 14 Wang, J., Liu, K.X., Ariani, F., et al. Probiotics for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of high-quality randomized controlled trials. PLoS One, 8, 2013, e83934.
15. 15 Bo, L., Li, J., Tao, T., et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst Rev, 10, 2014, CD009066.
16. 16 2015 Canadian Practice Guidelines. http://www.criticalcarenutrition.com/docs/CPGs%202015/Summary%20CPGs%202015%20vs%202013.pdf. Accessed December 27, 2016.
17. 17 Rongrungruang, Y., Krajangwittaya, D., Pholtawornkulchai, K., et al. Randomized controlled study of probiotics containing Lactobacillus casei (Shirota strain) for prevention of ventilator-associated pneumonia. J Med Assoc Thai 98:3 (2015), 253–259.
18. 18 Zeng, J., Want, C.T., Zhang, F.S., et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med 42:6 (2016), 1018–1028.
19. 19 Banupriya, B., Biswal, N., Srinivasaraghavan, R., Narayanan, P., Mandal, J., Probiotic prophylaxis to prevent ventilator associated pneumonia in children on mechanical ventilation: an open-label randomized controlled trial. Intensive Care Med 41:4 (2015), 677–685.
20. 20 Hempel, S., Newberry, S.N., Maher, A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307:18 (2012), 1959–1969.
21. 21 Jafarnejad, S., Shab-Bidar, S., Speakman, J.R., et al. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (>65 years): a meta-analysis. Nutr Clin Pract 31:4 (2016), 502–513.
22. 22 Goldenberg, J.Z., Ma, S.S., Saxton, J.D., et al. Probiotics for the prevention of Clostridium difficile–associated diarrhea in adults and children. Cochrane Database Syst Rev, 5, 2013, CD006095.
23. 23 Lau, C.S., Chamberlain, R.S., Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med 9 (2016), 27–37.
24. 24 McFarland, L.V., Probiotics for the primary and secondary prevention of Clostridium difficile infections: a meta-analysis and systematic review. Antibiotics 4:2 (2015), 160–178.
25. 25 Mihatsch, W.A., Braegger, C.P., Decsi, T., et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr 31:1 (2012), 6–15.
26. 26 Lytvyn, L., Quach, K., Banfield, L., Johnston, B.C., Mertz, D., Probiotics and synbiotics for the prevention of postoperative infections following abdominal surgery: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect 92:2 (2016), 130–139.
27. 27 Arumugam, S., Lau, C.S., Chamberlain, R.S., Probiotics and synbiotics decrease postoperative sepsis in elective gastrointestinal surgical patients: a meta-analysis. J Gastrointest Surg 20:6 (2016), 1123–1131.
28. 28 Schwenger, E.M., Tejani, A.M., Loewen, P.S., Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev, 12, 2015, CD00877.
29. 29 Shukla, S., Shukla, A., Mehboob, S., Guha, S., Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 33:6 (2011), 662–671.
30. 30 Xu, J., Ma, R., Chen, L.F., Zhao, L.J., Zhang, R.B., Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary Pancreat Dis Int 13:4 (2014), 354–360.
31. 31 Besselink, M.G.H., van Santvoort, H.C., Buskens, E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo-controlled trial. Lancet 371:9613 (2008), 651–659.
32. 32 Morrow, L.E., Gogineni, V., Malesker, M.A., Synbiotics and probiotics in the critically ill after the PROPATRIA trial. Curr Opin Nutr 15:2 (2012), 147–150.
33. 33 Kotzampassi, K., Giamarellos-Bourboulis, E.J., Voudouris, A., Kazamias, P., Eleftheriadis, E., Benefits of a synbiotic formula (Synbiotic 2000Forte®) in critically ill trauma patients: early results of a randomized controlled trial. World J Surg 30:10 (2006), 1848–1855.
34. 34 Rayes, N., Seehofer, D., Muller, A.R., et al. Influence of probiotics and fibre on the incidence of bacterial infections following major abdominal surgery—results of a prospective trial. Z Gastroenterol 40:10 (2002), 869–876.
35. 35 Rayes, N., Seehofer, D., Theruvath, T., et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation: a randomized, double-blind trial. Am J Transplant 5:1 (2005), 125–130.
36. 36 Didari, T., Solki, S., Mozaffari, S., Nikfar, S., Abdollahi, M., A systematic review of the safety of probiotics. Expert Opin Drug Saf 13:2 (2014), 227–239.
37. 37 https://www.ftc.gov/news-events/press-releases/2010/12/dannon-agrees-drop-exaggerated-health-claims-activia-yogurt. Acessed December 27, 2016.
38. 38 Sanders, M.E., Shane, A.L., Merenstein, D.J., Advancing probiotic research in humans in the United States: challenges and strategies. Gut Microbes 7:2 (2016), 97–100.
39. 39 Zaborin, A., Smith, D., Garfield, K., et al. Membership and behavior of ultra-low diversity pathogen communities present in the gut of humans during prolonged critical illness. MBio 5 (2014), e1361–e1414.
40. 40 Ojima, M., Motooka, D., Shimizu, K., et al. Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute phase of intensive care unit patients. Dig Dis Sci 61:6 (2016), 1628–1634.
41. 41 McDonald, D., Ackermann, G., Khailova, L., et al. Extreme dysbiosis of the microbiome in critical illness. mSphere 1:4 (2016), e00199–e00216.
42. 42 Sokol, H., Pigneur, B., Watterlot, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:43 (2008), 16731–16736.